Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Thai politician indicted for royal insult over vaccine speech

A prominent Thai politician faces up to 20 years in prison following his indictment on Monday for insulting the king and violating a cyber law, after he criticised the government for over-reliance on a royal-owned firm to supply COVID-19 vaccines.

Reuters

How Russia’s Ukraine invasion doomed the Sputnik V coronavirus vaccine

Manufacturing of the vaccine has slowed and further research is stalled

The Independent UK

India extends COVID-19 booster shots to all adults

India has begun offering booster doses of COVID-19 vaccine to all adults but is limiting free shots at government centers to front-line workers and people over age 60

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Evusheld procurement plan gets CCSA approval

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Bangkok Post

AstraZeneca Bets $25M On Preclinical Bispecific Antibody

Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and…

Benzinga

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

Benzinga

Why Big Pharma loves Tim Scott

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Salon

Big Pharma is betting on bigger political ambitions from Sen. Tim Scott

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

Tribune News Service

How does the COVID-19 prevention drug Evusheld work and who should receive it? An infectious disease specialist explains

The U.S. Food and Drug Administration granted emergency use authorization to AstraZeneca’s COVID-19 antibody drug Evusheld on Dec. 8, 2021. Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.

The Conversation

LV=’s on board with £511,000 bonus for boss despite shambles of failed sale

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

The Guardian - UK

World moves from shortages to possible glut of Covid-19 vaccines

NEW YORK: After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.

The Times of India

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Evusheld is becoming hard to find

As immunocompromised people work to get a potentially life saving covid therapy, it's becoming harder to locate

Bangkok Post

AstraZeneca steps up to tackle climate change

As the world's leading biopharmaceutical company, AstraZeneca understands how crucial it is to push the boundaries of science and deliver life-changing medicines in record time. The strong dedication to creating a better and healthier future for all, including those living in Thailand, is attested by supplying over 2.8 billion doses…

Pedestrian.tv

Do I Need A Booster If I’ve Had The Spicy Cough & All Your Other Third Dose Questions Answered

If you're yet to get your third dose of a COVID-19 vaccine, we answer all of your vaccine questions in the below.

The Independent UK

EU regulator advises AstraZeneca's COVID drug be cleared

The European Union's drug regulator says it's recommending that an antibody drug developed by AstraZeneca be authorized to help people avoid getting sick with the coronavirus

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld

EMA's human medicines committee (CHMP) has

Benzinga

AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study

AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) and chemoradiotherapy did not achieve the primary goal of improving survival in patients with locally advanced cervical cancer. The Phase 3 study, dubbed "CALLA," tested progression-free survival of patients with the combination against chemoradiotherapy alone. "While the results were not what we hoped for, insights from the trial…

Manchester Evening News

Tragedy as girl, 18, dies of blood clot two weeks after Covid vaccine

Kasey Turner experienced 'thunder clap' headaches from thrombosis in her sinus cavity

Bangkok Post

Testament to protecting millions of lives

The race against time to safely develop and quickly deliver a life-saving COVID-19 vaccine around the world serves as AstraZeneca's testament to protecting the lives of billions of people while addressing one of the biggest healthcare crises facing humankind.

Wales Online

Student paramedic, 18, died of clot two weeks after having Covid vaccine

Kasey suffered the worst headache of her life and went to hospital, where she died four days later

Daily Record

'Healthy' teen dies just days after suffering 'thunderclap headache' from Covid jab

Kasey Turner was rushed to intensive care with an acute onset headache last February.

Daily Mirror

'Healthy' teen died after suffering 'thunderclap headache' following AstraZeneca Covid jab

Kasey Turner, 18, died four days after being admitted to Barnsley Hospital, having received her first dose of the AstraZeneca Covid vaccine

1 … 22 23 24 25

People

Thanakorn Wangboonkongchana

101 stories

Pascal Soriot

95 stories

Thanathorn Juangroongruangkit

51 stories

Patrick Jackson

31 stories

Taweesilp Visanuyothin

30 stories

McMorris Rodgers

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organisation

299 stories

Health Ministry

253 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.